- Brand names:
- Pharmaceutical Company:
- Condition/Indication: Presymptomatic treatment of spinal muscular atrophy (SMA)
- Meeting Date: July 2023
- Public Summary Document (PSD) July 2023 PBAC Meeting - (PDF 760KB)
- Public Summary Document (PSD) July 2023 PBAC Meeting - (Word 133KB)
Onasemnogene abeparvovec – July 2023
Onasemnogene abeparvovec: Solution for injection, customised based on patient weight; Zolgensma®
Last updated
27 October 2023